Overcoming resistance to virotherapy of hepatobiliary, gastrointestinal and non-gastrointestinal tumors

Introduction: Tumor resistances to oncolytic viruses endanger the broad clinical success of virotherapy which is at the edge to receive approval of a first virotherapeutic compound in the near future. Measles vaccine viruses (MeV) have shown to possess profound oncolytic capabilities but are hypothesized as every other viral vector system to be confronted with severe primary and acquired resistances in diverse tumor entities. Aim: We aimed at identifying mechanisms especially of primary resistance against our prototypic suicide gene armed oncolytic vector MeV-SCD and searched for simple ways to overcome such res…